Cyclosporine-induced syngeneic graft-versus-host disease: assessment of T cell differentiation
Hess, A.D.; Vogelsang, G.B.; Heyd, J.; Beschorner, W.E.
Transplantation Proceedings 19(1 Part 3): 2683-2686
1987
ISSN/ISBN: 0041-1345 PMID: 3547947 Document Number: 300801
Document emailed within 1 workday
Related Documents
Dale, B.M.; Atkinson, K.; Kotasek, D.; Biggs, J.C.; Sage, R.E. 1989: Cyclosporine-induced graft vs host disease in two patients receiving syngeneic bone marrow transplants Transplantation Proceedings 21(5): 3816-3817Przepiorka, D.; Shapiro, S.; Schwinghammer, T.L.; Bloom, E.J.; Rosenfeld, C.S.; Shadduck, R.K.; Venkataramanan, R. 1991: Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease Bone Marrow Transplantation 7(6): 461-465
Hess, A.D.; Fischer, A.C.; Beschorner, W.E. 1989: Regulation of syngeneic graft-versus-host disease by autosuppressor mechanisms Transplantation Proceedings 21(1 Pt 3): 3013-3015
Gluckman, E.; Devergie, A.; Sohier, J.; Saurat, J.H. 1980: Graft-versus-host disease in recipients of syngeneic bone marrow Lancet 1(8162): 253-254
Mengarelli, A.; Iori, A.Paola.; Romano, A.; Cerretti, R.; Cerilli, L.; De Propris, M.Stefania.; Fenu, S.; Moleti, M.Luisa.; De Felice, L.; Girelli, G.; Arcese, W. 2003: One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation Haematologica 88(3): 315-323
Cooper, M.H.; Hartman, G.G.; Starzl, T.E.; Fung, J.J. 1991: The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506 Transplantation Proceedings 23(6): 3234-3235
Spaner, D.; Lowsky, R.; Fyles, G.; Lipton, J.H.; Banerjee, D.; Ng, C.M.; Wade, J.A.; Messner, H.A. 1998: Acute intestinal graft-versus-host disease in a syngeneic bone marrow transplant recipient Transplantation 66(9): 1251-1253
Hard, R.C. 1975: Hyperimmunoglobulinaemia, T-cell deficiency and plasmacytosis in RFM mice with host versus graft disease induced by the perinatal inoculations (T6XRFM)F1 spleen cells Clinical and Experimental Immunology 22(2): 330-340
Schwinghammer, T.L.; Bloom, E.J.; Rosenfeld, C.S.; Wilson, J.W.; Przepiorka, D.; Shadduck, R.K. 1995: High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease Bone Marrow Transplantation 16(1): 147-154
Sullivan, K.M.; Siadak, M.F.; Witherspoon, R.P. 1990: Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation Transplantation Proceedings 22(3): 1336-1338
Deeg, H.J.; Spitzer, T.R.; Cottler-Fox, M.; Cahill, R.; Pickle, L.W. 1991: Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis Bone Marrow Transplantation 7(3): 193-198
Dey, B.; Yang, Y.G.; Preffer, F.; Shimizu, A.; Swenson, K.; Dombkowski, D.; Sykes, M. 1999: The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model Transplantation 68(1): 141-149
You-Ten, K.E.; Lapp, W.S. 1996: The role of endogenous glucocorticoids on host T cell populations in the peripheral lymphoid organs of mice with graft-versus-host disease Transplantation 61(1): 76-83
Tollemar, J.; Ringdén, O.; Heimdahl, A.; Lönnqvist, B.; Sundberg, B. 1988: Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate Transplantation Proceedings 20(3 Suppl 3: 470-479
Wall, D.A.; Hamberg, S.; Ferrara, J.L.; Abbas, A.K. 1989: Immunodeficiency in graft-versus-host disease (GVHD). II. Effects of GVHD-induced suppressor cells on CD4+ T cell clones Journal of Immunology 143(1): 74-78
Mrsić, M.; Labar, B.; Bogdanić, V.; Nemet, D.; Pavletić, Z.; Plavsić, F.; Dobrić, I.; Kastelan, A.; Marusić, M.; Zupancić-Salek, S. 1989: Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias Bone Marrow Transplantation 4(Suppl): 95-96
Ushiyama, C.; Hirano, T.; Miyajima, H.; Okumura, K.; Ovary, Z.; Hashimoto, H. 1995: Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease Journal of Immunology 154(6): 2687-2696
Atkinson, K.; Downs, K. 1995: Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation Bone Marrow Transplantation 16(6): 755-758
Cahn, J.Y.; Bordigoni, P.; Tiberghien, P.; Milpied, N.; Brion, A.; Widjenes, J.; Lioure, B.; Michel, G.; Burdach, S.; Kolb, H.J. 1995: Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. a multicenter phase IIi study Transplantation 60(9): 939-942
Via, C.S.; Rus, V.; Gately, M.K.; Finkelman, F.D. 1994: IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease Journal of Immunology 153(9): 4040-4047